Therapix Biosciences Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Givatayim Israel (2004)
Status: Acquired by FSD Pharma (2018)

Organization Overview

First Clinical Trial
2009
NCT00915187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NasVax Ltd | Therapix Biosciences Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: Therapix Biosciences Ltd. (0) Acquired (1)

mupirocin (bactroban) (1 trial)

Drugs in Phase 3 Trials (1)

palmitoylethanolamide (3 trials)

Drugs in Phase 2 Trials (7)

Key: Therapix Biosciences Ltd. (5) Acquired (2)

chlorhexidine (hibitane) (1 trial)

dronabinol (marinol) (2 trials)

Exeporfinium (2 trials)

inactivated influenza vaccine (1 trial)

muromonab cd3 (Orthoclone OKT3) (1 trial)

sodium chloride (1 trial)

teplizumab (Tzield) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Apnea (Phase 2)

Fatty Liver (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Influenza, Human (Phase 2)

Metabolic Syndrome (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Syndrome (Phase 3)

Tourette Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9